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Abstract
Background Osteoarthrosis is characterized by cartilage
erosion, proteolysis of aggrecan and collagen, and disturbed
rates of synthesis of aggrecan and hyaluronan by chondrocytes,
with hyaluronan over-production being an early reaction. We
considered that inhibition of hyaluronan export might prevent
subsequent proteoglycan loss and collagen degradation.
Methods To test this hypothesis, we studied a tissue culture
model using bovine cartilages explants activated with IL-1α to
induce osteoarthritic reactions using the phosphodiesterase-5
inhibitors tadalafil, zaprinast and vardenafil.
Results These drugs inhibited hyaluronan export, but they did
not inhibit hyaluronan synthase activity. Simultaneously, they
inhibited proteoglycan loss and collagen degradation, but not
their synthesis. They also reduced the release of gelatinases into
the culture media and diffusion of the indicator protein
horseradish peroxidase through the cartilage explants. The
mechanism of action of these compounds may be through
inhibition of hyaluronan exporter multidrug resistance-
associated protein 5 (MRP5), because the effective drug
concentrations were much higher than required for
phosphodiesterase-5 inhibition and intracellular cGMP
accumulation.
Conclusion Inhibition of hyaluronan over-production may be an
appropriate target to attenuate IL-1-induced reactions in
osteoarthritic cartilage.
Introduction
Destruction of joint cartilage is the major outcome of arthritic
diseases such as osteoarthrosis and rheumatoid arthritis.
Although chondrocytes represent only 5% of the tissue, these
cells are responsible for cartilage matrix synthesis, which con-
sists of two main components: the network of type II collagen,
which provides the tensile strength and stiffness; and the large
aggregating proteoglycan aggrecan, which is responsible for
the osmotic swelling capability and elasticity. Aggrecan deco-
rates a backbone of hyaluronan that is partially anchored in the
plasma membrane of chondrocytes at the hyaluronan synthase
site and is further bound by the cell surface receptor CD44.
Aggregate formation is important from a physiological point of
view because it ensures the retention of aggrecan within the
collagen network.
The biosyntheses of hyaluronan and proteoglycans take place
via different mechanisms and occur in different compartments
[1]. Proteoglycans are synthesized in the Golgi and exocy-
tosed by vesicles. Hyaluronan is polymerized at the inner side
of plasma membranes [1-4] and was originally thought to be
exported by the synthase itself [5,6], but recently the ATP-
binding cassette transporter multidrug resistance protein
(MRP)5 was identified as a hyaluronan exporter [7,8]. Both
components aggregate in the extracellular matrix [9], with up
to 200 aggrecan molecules decorating one hyaluronan chain
[10]. In healthy cartilage, the hyaluronan and aggrecan are
synthesized and degraded at similar rates [11], whereas the
turnover of collagens is much slower [12]. The proteoglycan
monomer is liberated from the hyaluronan binding region by
aggrecanases, matrix metalloproteases and cathepsins [13-
17]. In healthy cartilage, most of hyaluronan is removed by
endocytosis through the CD44 receptor [18], whereas in
osteoarthritic cartilage about 90% is liberated into the environ-
ment [19]. Aggrecan leaves cartilage either as intact molecule
or after proteolysis, depending on the stimulus [20].
HABP = hyaluronan binding protein; HRPO = horseradish peroxidase; IL = interleukin; MMP = matrix metalloprotease; MRP = multidrug resistance-
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Key events in osteoarthritic cartilage are increased hyaluronan,
decreased aggrecan synthesis [19,21], and proteolytic cleav-
age of collagen type II and aggrecan core protein [22,23]. For
a long time it was believed that proteolytic degradation of col-
lagen and aggrecan was the primary event in cartilage break-
down. Much effort to develop protease inhibitors led to
compounds that were chondroprotective in vitro or in animal
models [24-27], but the findings of clinical trials were equivo-
cal [28,29].
Recently, we discovered that a variety of multidrug resistance
inhibitors interfered with hyaluronan export by the the multid-
rug resistance-associated protein MRP5 [7,8]. Some of the
hyaluronan export inhibitors have already been applied to pre-
vent hyaluronan over-production and proteoglycan loss in IL-
1α activated chondrocyte cell cultures, in cartilage organ cul-
tures and in an animal model of osteoarthrosis [30]. Because
hyaluronan export by MRP5 is regulated by intracellular cGMP
[8] (also an MRP5 substrate [31]), we evaluated the effects of
the drugs zaprinast, vardenafil and tadalafil. These agents are
structural analogues of cGMP that inhibit the cGMP-specific
phosphodiesterase (PDE5) at nanomolar concentrations [32]
and so they increase intracellular cGMP levels. In addition,
zaprinast is also known as a MRP5 inhibitor [33]. We analyzed
their effects on hyaluronan export, proteoglycan loss and col-




Articular cartilage was obtained from the knees of 2-year-old
steer provided by a local slaughterhouse. Vardenafil was from
Bayer AG (Leverkusen, Germany), tadalafil was from Elli Lilly
(Indianapolis, IA, USA), hyaluronan binding protein (HABP)
was from Calbiochem (Schwalbach, Germany), and hyaluro-
nan (Healon®) was a gift from Genzyme (Cambridge, MA,
USA). Polyclonal antibodies to matrix metalloprotease
(MMP)9 were from Biomol (Hamburg, Germany). Additional
chemicals were from Sigma-Aldrich Chemical Corporation
(Taufkirchen, Germany).
General methods
The hyaluronan synthase activity was determined by incorpo-
ration of radioactive [14C]glucuronic acid from UDP-
[14C]GlcA and UDP-GlcNac [7]. The cytotoxicity of the drugs
was measured as described previously [34]. For all experi-
ments, the weight of the explants was determined immediately
after cutting to minimize evaporation and the data were related
to wet weight.
Determination of hyaluronan
Cartilage explants were incubated in the absence or presence
of IL-1 (2 ng/ml) and the inhibitors at various concentrations in
serum-free Dulbecco's medium for 3 days. The amount of
hyaluronan released into the culture medium was determined
using biotinylated HABP, as described previously [30].
Determination of proteoglycans
Cartilage explants were weighed (average wet weight 20 mg)
and incubated in the absence and presence of IL-1 (2 ng/ml)
and the inhibitors at various concentrations for 5 days. The tis-
sues were extracted with 1.5 ml of a solution of 4 mol/l gua-
nidinium hydrochloride, 0.1 mol/l ε-aminohexanoid acid, 5
mmol/l benzamidine, 10 mmol/l N-ethylmaleinimide and 0.5
mmol/l phenalmethylsulfonyl fluoride for 3 days at 4°C. The
solution was centrifuged for 5 minutes at 10.000 g and the
proteoglycans were determined in the supernatant using the
alcian blue method, as described previously [35].
Determination of the proteoglycan synthesis
Chondrocytes were cultured in alginate beads, as described
above, and supplemented with 25 μl [35S]sulphate (0.5 mCi/
ml) for 24 hours. The beads were washed three times with 102
mmol/l CaCl2 to remove un-incorporated radioactivity and dis-
solved in 55 mmol/l sodium citrate. Proteoglycans were iso-
lated by the alcian blue precipitation method [36] and aliquots
were used in the determination of radioactivity.
Measurement of degraded collagen
The procedure for measurement of degraded collagen is
described in detail in the report by Kosaki and coworkers [37].
Cartilage explants were cultured in Dulbecco's medium for 28
days in the presence or absence of IL-1 (2 ng/ml), IL-17 (25
ng/ml), 2 μmol retinoic acid and hyaluronan export inhibitors,
and media were changed every 2 days. The cartilage was
weighed and extracted with 4 mol/l guanidinium hydrochloride
in 0.1 mol/l Tris HCl (pH 7.3), 1 mmol/l Iodoacetamide, 1
mmol/l EDTA, and 10 μg/ml pepstatin A for 72 hours. The
extracted explants were washed with 1 mmol/l iodoacetamide
and 1 mmol/l EDTA, and 10 μg/ml pepstatin in 0.1 mol/l Tris-
HCl (pH 7.3) three times for 2 hours. The denatured collagen
was digested overnight at 37°C with a solution of 0.5 ml of α-
chymotrypsin (0.5 mg/ml) in 1 mmol/l iodoacetamide and 1
mmol/l EDTA, and 10 μg/ml pepstatin in 0.1 mol/l Tris-HCl
(pH 7.3). The mixture was centrifuged for 8 minutes at 10,000
g, and the supernatant containing the digested collagen was
separated from the remaining insoluble matrix containing the
intact collagen. The insoluble material was hydrolyzed with
500 μl of 6 mol/l HCl at 110°C for 20 hours. The hydrolysate
was neutralized with 500 μl of 6 mol/l NaOH and undissolved
material was removed by centrifugation. The amount of the col-
lagen-specific amino acid hydroxyproline was determined. An
aliquot (25 μl) was mixed with 975 μl citrate buffer (57 g
sodium acetate, 37.5 g sodium citrate, 5.5 g citric acid and
385 ml 2-propanol in 1 l water). An aliquot (200 μl) of this mix-
ture was added to 100 μl of a solution of 100 mg chloramine
T in 1 ml water, 2 ml 2-propanol and 3 ml citrate buffer. After
20 minutes at room temperature, 100 μl of 6.2 mol/l perchloric
acid was added and reacted for 12 minutes at roomAvailable online http://arthritis-research.com/content/10/1/R8
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temperature. A solution of 100 μl Ehrlichs reagent (500 mg in
1.25 ml ethanol and 1.25 ml diethyleneglycol-monoethylether)
was added and incubated at 60°C for 20 minutes. The adsorp-
tion was read at 565 nm and the content of hydroxyproline was
calculated using 1 to 30 μg/ml calibration samples.
Determination of collagen synthesis
Chondrocytes were cultured in alginate beads for 1 week with
10% foetal calf serum in Dulbecco's medium. The medium
was changed and supplemented with 1 mmol/l cysteine, 1
mmol/l pyruvate, 60 μg/ml β-aminopropionitril and 25 μg/ml
ascorbic acid, and the beads were incubated for an additional
24 hours. The medium was replaced with serum-free medium
containing the above supplements, IL-1, the inhibitors and
[14C]proline (2 μCi/ml), and the cells were incubated for 24
hours. The beads were washed three times with 0.9% NaCl
and CaCl2 (116 mg/l) for 30 minutes to remove unincorpo-
rated radioactivity, dissolved in 500 μl of 55 mmol/l sodium cit-
rate, and the radioactivity was determined.
Zymography of matrix proteases
Bovine cartilage explants were cultured in serum-free Dul-
becco's medium for 5 days in the presence or absence of IL-
1α (2 ng/ml) and 10 or 30 μmol/l zaprinast, vardenafil, or
tadalafil. The protein concentrations of the culture media were
determined and equal amounts of proteins were directly
applied to a 7.5% SDS-polyacrylamide gel that contained
0.1% gelatin. After electrophoresis, the gel was washed twice
with 2.5% Triton X-100 for 30 minutes, three times with water
for 10 minutes, and incubated in a solution of 50 mmol/l Tris-
HCl, 5 mmol/l CaCl, 1 μmol/l ZnSO4 (pH 8.0) for 5 days at
37°C. The gel was stained with Coomassie blue.
Determination of protein infiltration into the cartilage 
matrix
Bovine cartilage explants were cultured in Dulbecco's medium
and 10% foetal calf serum in the presence or absence of IL-
1α (2 ng/ml) and the drugs zaprinast, tadalafil and vardenafil
for 14 days. Pieces of 2 mm diameter and a volume of 3.15
mm3 were punched out. They were incubated in a solution of
10 units/ml of horseradish peroxidase (HRPO) in phosphate-
buffered saline for 1 hour at 37°C. The pieces were rinsed with
water and shaken in 250 μl phosphate-buffered saline over-
night at 4°C to release the infiltrated enzyme. The concentra-
tions of HRPO were determined in 50 μl of the supernatants.
A solution (150 μl) of ABTS (2,2'-azino-bis [3-ethylbenzthiazo-
line-6-sulfonic acid]; 1 mg/ml) and 0.03% H2O2 was added,
and after incubation for 30 minutes at 37°C the adsorbance at
405 nm was read.
Statistical analyses
Data are presented in the figures as mean ± standard devia-
tion. The t-test was used, and a P value below 0.05 was con-
sidered statistically significant.
Results
Inhibition of hyaluronan export
The drugs tadalafil, zaprinast and vardenafil were analyzed for
their effects on hyaluronan export from bovine cartilage
explants in tissue culture. Cartilage explants were incubated
for 3 days in the presence and absence of IL-1α and increas-
ing concentrations of the drugs. Figure 1a shows that IL-1α
stimulated an increase in hyaluronan export by about sixfold,
and the inhibitors partially reversed it. In control experiments,
the inhibitors were analyzed for their effect on the hyaluronan
synthase activity of chondrocytes cultured in alginate beads.
Activity was reduced by less than 20% up to concentrations
of 400 μmol/l (Figure 1b). The toxicity of the drugs was less
than 10% at a concentration of 100 μmol/l for the three
inhibitors.
Figure 1
Inhibition of hyaluronan export in bovine chondrocytes Inhibition of hyaluronan export in bovine chondrocytes. (a) Cartilage 
explants were incubated in the absence and presence of IL-1α and the 
drugs tadalafil (❍), zaprinast (), or vardenafil (). The concentration of 
hyaluronan was determined in the supernatant after 3 days. The error 
bars indicate the standard deviation of three determinations. (b) Effect 
of inhibitors on hyaluronan synthase activity. A particulate fraction of 
chondrocytes was prepared and incubated with the substrates UDP-
GlcNac and UDP-[14C]GlcA and increasing concentrations of tadalafil 
(❍), zaprinast (), or vardenafil (), and the incorporation into 
[14C]hyaluronan was determined.Arthritis Research & Therapy    Vol 10 No 1    Deiters and Prehm 
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Inhibition of proteoglycan loss
The drugs tadalafil, zaprinast and vardenafil were analyzed for
their effects on proteoglycan loss from IL-1α activated bovine
cartilage explants. Proteoglycans were extracted from the tis-
sues with guanidinium hydrochloride and determined colouri-
metrically. Figure 2a shows that IL-1α reduced the
proteoglycan content in cartilage to less than 40% of that in
the untreated control. The inhibitors protected the cartilage
from proteoglycan loss. In a control experiment, the effect of
the inhibitors on the proteoglycan synthesis rate was deter-
mined. Bovine chondrocytes were cultured in alginate beads
and incubated with [35S]sulphate in the presence of drugs,
and inhibition of proteoglycan synthesis was found to be
reduced by less than 25% (Figure 2b). These findings confirm
earlier observations obtained with other drugs [30] and sug-
gest that zaprinast, vardenafil and tadalafil prevented prote-
oglycan loss from osteoarthritic cartilage primarily by inhibition
of hyaluronan over-production.
Inhibition of collagen degradation
The drugs were analyzed for their effects on collagen degrada-
tion in IL-1α activated cartilage explants. Preliminary experi-
ments revealed that induction of osteoarthritic reactions by IL-
1α was not sufficient to detect measurable amounts of colla-
gen degradation products. Degradation can be enhanced
substantially by addition of IL-17 and retinoic acid. Therefore,
these activators were added. Activated cartilage explants
were incubated with tadalafil, zaprinast, or vardenafil for 28
days, extracted with guanidinium hydrochloride, and digested
with chymotrypsin. Degraded collagen was measured as the
amount of hydroxyproline that was susceptible to chymot-
rypsin. Figure 3a shows that cartilage activation reduced the
amount of chymotrypsin-resistant collagen to 65%. Inhibition
of hyaluronan export restored the content of intact collagen. In
a control experiment, the effect of zaprinast on collagen syn-
thesis was measured (Figure 3b). Bovine chondrocytes were
cultured in alginate beads and incubated in culture medium
containing [14C]proline in the absence and presence of zapri-
nast and incorporation of radioactivity into pepsin-resistant
collagen was determined. The total amount of collagen was
not altered significantly at concentrations up to 100 μmol/l
zaprinast. These findings suggest that the drugs did not affect
collagen synthesis and that the protection from collagen deg-
radation could involve other mechanisms.
Inhibition of the action of gelatinases
A possible explanation for the protective effect of hyaluronan
export inhibition on collagen degradation could be that the
altered composition and permeability of osteoarthritic cartilage
allowed the diffusion of metalloproteases. It is known that
chondrocytes produce gelatinases, particularly if they are acti-
vated by IL-1 [38]. We tested this possibility by measuring the
release of gelatinases from IL-1α activated cartilage. Cartilage
explants were incubated in the absence and presence of IL-1α
and vardenafil, and enzymes released from the cartilage
explants were analyzed by gel zymography. We also included
dibutyryl-cGMP in the analysis, because cGMP has been
shown to mediate IL-1 signalling in chondrocytes [39]. Figure
4a shows three bands with molecular weights of 86 kDa, 66
kDa and 62 kDa. The upper band was probably pro-MMP9,
because it reacted with monoclonal antibodies in Western
blots (data not shown). The lower two bands comigrated with
an authentic sample of pro-MMP2 and MMP2 gelatinases
(from Dr R Dreier; data not shown). IL-1α enhanced the
release of the gelatinases, and this release was not signifi-
cantly altered by addition of dibutyryl-cGMP. Vardenafil
reduced the gelatinase release in a concentration-dependent
Figure 2
Inhibition of proteoglycan loss in bovine chondrocytes Inhibition of proteoglycan loss in bovine chondrocytes. (a) Cartilage 
explants were incubated in the absence and presence of IL-1α and the 
drugs tadalafil, zaprinast, or vardenafil at concentrations of 50 μmol/l. 
The tissues were weighed, extracted with guanidinium hydrochloride, 
and the amount of proteoglycans was determined after 5 days. The 
data were related to controls without IL-1α as 100%. The error bars 
represent the standard deviation of three determinations; *P < 0.05. (b) 
Effect of inhibitor tadalafil (❍), zaprinast (), or vardenafil () on prote-
oglycan synthesis. Bovine chondrocytes were cultured in alginate 
beads and incubated with increasing concentrations of the inhibitors in 
the presence of [35S]sulphate. After 24 hours the radioactivity incorpo-
rated into [35S]proteoglycans was determined.Available online http://arthritis-research.com/content/10/1/R8
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manner. Similar results were obtained with zaprinast and
tadalafil (data not shown).
In a control experiment, we analyzed whether inhibition of
hyaluronan export altered the syntheses of gelatinases by
chondrocytes in unstimulated cartilage explants. The explants
were incubated in the absence and presence of 100 μmol/l
zaprinast, vardenafil and tadalafil, respectively, and the gelati-
nase activities were again analyzed by gel zymography. Figure
4b shows no differences in enzyme activities between the
samples. These results showed that inhibition of hyaluronan
export in IL-1 activated cartilage explants inhibited the release
of gelatinases into the culture medium.
Inhibition of protein diffusion through cartilage explants
If the altered composition of arthritic cartilage with increased
hyaluronan and decreased proteoglycan content was respon-
sible for facilitated diffusion of degrading enzyme through the
matrix, exogenous enzymes should infiltrate better. This
hypothesis was tested using HRPO as an indicator protein.
Cartilage explants were incubated in the absence or presence
of IL-1α and zaprinast, vardenafil, or tadalafil in increasing con-
centrations. The explants were incubated with the indicator
protein HRPO to allow diffusion into the cartilage. After
Figure 3
Quantitative analysis of collagen degradation and its inhibition Quantitative analysis of collagen degradation and its inhibition. (a) Car-
tilage explants were incubated with IL-1α, IL-17 and retinoic acid in the 
absence or presence of zaprinast, tadalafil, or vardenafil at concentra-
tions of 50 μmol/l for 4 weeks at 37°C. The amount of chymotrypsin-
resistant collagen was determined as hydroxyproline. The values were 
related to the control that contained 23 μg hydroxyproline/mg cartilage 
as 100%. The bars indicate the standard deviation of four determina-
tions; *P < 0.05. (b) Bovine chondrocytes were grown in alginate 
beads and and collagen was labeled by incorporation of [14C]proline in 
the absence or presence of 30 μmol/l and 100 μmol/l zaprinast. The 
amount of [14C]collagen within the alginate beads was determined 
after 24 hours. The bars indicate the standard deviation of four 
determinations.
Figure 4
Effect on gelatinases Effect on gelatinases. (a) Inhibition of gelatinase liberation from bovine 
cartilage explants. Cartilage explants were incubated in the absence or 
presence of IL-1α and 25 μmol/l dibutyryl-cGMP or 10 μmol/l or 30 
μmol/l vardenafil for 4 days at 37°C. The lanes marked with (-) indicate 
two independent control experiments with IL-1 only. The activity of gela-
tin-degrading enzymes released into the culture supernatant was deter-
mined by zymography. (b) Unaffected gelatinase synthesis. 
Unstimulated explants were incubated for 10 days in the absence and 
presence of 100 μmol/l zaprinast, vardenafil and tadalafil, and the gela-
tinase activities were again analyzed by gel zymography. MMP, matrix 
metalloprotease.Arthritis Research & Therapy    Vol 10 No 1    Deiters and Prehm 
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extensive washing, the explants were further incubated in
phosphate-buffered saline to liberate the infiltrated enzyme.
The amount of liberated enzyme was determined by a colour
reaction. Control experiments indicated that the drugs did not
have any direct effect on the peroxidase activity at micromolar
concentrations. Figure 5 shows that IL-1α treatment led to an
increase of enzyme infiltration of about 350% over the unstim-
ulated control (100%). Inhibition of hyaluronan export reduced
the IL-1α induced enzyme infiltration almost to control values.
Mechanism of inhibitor action
There are two possible mechanisms for the inhibitory action of
the drugs zaprinast, vardenafil and tadalafil. Because of their
PDE5 inhibitory activity, with Ki values of 300 nmol/l for zapri-
nast, 1.5 nmol/l for vardenafil and 2.9 nmol/l for tadalafil
[40,41], they will certainly raise the concentration of intracellu-
lar cGMP that could inhibit hyaluronan export by MRP5 [8]. It
is also possible that they additionally act as MRP5 inhibitors,
because they are structural analogues of cGMP; also, it is
known that zaprinast inhibits transport at concentrations
between 20 nmol/l and 250 μmol/l, depending on the trans-
ported substrate [33,42,43]. If the drugs acted only through
inhibition of PDE5, then also other unrelated PDE5 inhibitors
or addition of other cGMP analogs should have similar effects.
We therefore analyzed hyaluronan export, proteoglycan loss
and collagen degradation of IL-1 activated cartilage explants in
the presence of dibutyryl-cGMP and ODQ (1H-[1,2,4]-oxadi-
azolo [4,3a]quinoxaline-1-one), which is a selective inhibitor of
the soluble nitric oxide inducible guanylate cyclase. Figure 6
shows that none of the parameters was significantly altered by
these treatments. Similar results were obtained with bromo-
cGMP (data not shown). These findings suggest that altera-
tions of the intracellular cGMP concentration did not account
Figure 5
Inhibition of protein infiltration into bovine cartilage explants Inhibition of protein infiltration into bovine cartilage explants. Cartilage 
explants were incubated in the absence or presence of IL-1α and (a) 
tadalafil, (b) zaprinast, or (c) vardenafil for 14 days at 37°C. The 
explants were then incubated with horseradish peroxidase as indicator 
protein for 1 hour. After washing, the amount of enzyme that had infil-
trated the explants was determined by a colour reaction. The error bars 
represent the standard deviation of eight determinations.
Figure 6
Influence of cGMP modulators Influence of cGMP modulators. Shown is the influence of cGMP modu-
lators on the hyaluronan (open bars), proteoglycan (solid bars), and col-
lagen (cross-hatched bars) production of bovine cartilage. Cartilage 
explants were cultured in the presence of 2 ng/ml IL-1 and the guan-
ylate cyclase inhibitor ODQ (1H-[1,2,4]-oxadiazolo [4,3a]quinoxaline-1-
one; 25 μmol/l) or dibutyryl-cGMP (25 μmol/l). The incubation periods 
were for 3 days for hyaluronan, 5 days for proteoglycans and 28 days 
for collagens. For stimulation of collagen degradation, the cartilage 
explants were supplemented with 25 ng/ml IL-17, and 2 μmol/l retinoic 
acid. The concentrations of hyaluronan in the supernatant, proteogly-
cans and collagen (as hydroxyproline) were determined as described 
under Materials and methods. The error bars represent the standard 
deviation of three determinations.Available online http://arthritis-research.com/content/10/1/R8
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for the inhibitory effects of the drugs zaprinast, vardenafil and
tadalafil.
Discussion
One of the earliest events in the pathogenesis of osteoarthritis
is hyaluronan over-production of chondrocytes that precedes
the stimulation of protease synthesis, collagen degradation
and cartilage destruction [44-46]. It can be induced by IL-1
treatment in cell and organ culture and in animal models of
osteoarthritis. IL-1 alters the cartilage composition by
influencing the transcription rate of enzymes and matrix com-
ponents [47].
In a previous report we showed that hyaluronan over-produc-
tion led to loss of proteoglycans from osteoarthritic cartilage
[30]. Inhibition of hyaluronan over-production normalized the
proteoglycan content on alginate cultures of bovine chondro-
cytes, in cartilage explants and in an animal model of osteoar-
throsis. We showed that enhanced intracellular cGMP levels
reduce hyaluronan export from fibroblasts [8]. In the present
study we extended the effect of hyaluronan export inhibitors to
collagen degradation. We used the drugs zaprinast, vardenafil
and tadalafil that were originally developed as PDE5 inhibitors
[32].
We showed here that the drugs inhibited hyaluronan export,
and protected cartilage from proteoglycan loss, release of
metalloproteases into the medium and collagen degradation.
The drugs did not influence substantially the rates of synthesis
of hyaluronan, proteoglycans, metalloproteases and collagens.
Our experiments also suggest a mechanism for how the inhib-
itors of hyaluronan export were able to prevent collagen deg-
radation. Hyaluronan over-production increased the infiltration
of the indicator protein HRPO into IL-1α treated cartilage, and
this infiltration was reduced by inhibition of hyaluronan export.
It is likely that this inhibition also applies to reduced diffusion
of proteoglycans and gelatinases MMP2 and MMP9 or other
degrading enzymes out of the cartilage or from their origin to
the targets within the cartilage.
The reason for the enhanced diffusion of proteins through
osteoarthritic cartilage can be found in the altered cartilage
composition. Proteoglycans at high concentrations in cartilage
play a critical role in the flow and diffusion of macromolecules.
Because of the high density of fixed charges, they vigorously
restrict diffusion [48,49]. If the dense packing of proteogly-
cans is lost and replaced by voluminous hyaluronan, degrad-
ing enzymes can freely reach their targets. It has indeed been
demonstrated that aggrecan protects cartilage collagen from
proteolytic degradation [50]. As a consequence of this sce-
nario, collagen is protected from degradation by inhibition of
hyaluronan export.
We also analyzed the mechanism of hyaluronan export inhibi-
tion. At nanomolar concentrations, the PDE5 inhibitors sub-
stantially elevate the intracellular cGMP levels [32]. Zaprinast
acts also as a MRP5 inhibitor in micromolar concentrations
[33]. Because the effects that we observed on hyaluronan
export, proteoglycan loss and collagen degradation were all
found in the micromolar range, it is likely that the drugs
primarily exerted their effects on export by MRP5 rather than
through an increase in intracellular cGMP levels. Although
based on a limited dataset, the rank order of potency for PDE5
inhibition of zaprinast (Ki = 300 nmol/l), tadalafil (Ki = 2.9
nmol/l) and vardenafil (Ki = 1.5 nmol/l) does not correlate with
the apparent potency of these compounds in inhibiting
hyaluronan export induced by IL-1 (Figure 1). This notion was
supported by our experiments that altered the intracellular
cGMP by the specific guanylate cyclase inhibitor ODQ and
the analogues dibutyryl-cGMP and bromo-cGMP. These com-
pounds did not have any significant effect on hyaluronan
export, proteoglycan loss and collagen degradation. The lack
of an effect by cGMP analogues on chondrocytes is surprising
and clearly different from the effects on fibroblasts [8]. Such
cell-dependent discrepancies of MRP5 inhibition were previ-
ously observed in other cell lines and are probably due to dif-
ferent MRP5 copy numbers per cell [43].
The drugs zaprinast, tadalafil and vardenafil have been devel-
oped for other disturbances and are certainly not ideal for
treatment of osteoarthrosis. It may be worthwhile to develop
specific hyaluronan export inhibitors, because they could not
only prevent proteoglycan loss and collagen degradation, but
also inhibit subsequent reactions that lead to apoptosis of
chondrocytes.
Conclusion
Inhibition of hyaluronan export from chondrocytes attenuated
proteoglycan loss, collagen degradation, protein diffusion and
metalloprotease activity in IL-1 activated cartilage and could
be effective in osteoarthrosis.
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